Alfredo Belcastro

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study.

Predictive Factors of Super-Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real-World Monocentric Study.

Journal: International journal of dermatology

Published: November 20, 2025

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement.

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement.

Journal: Dermatology reports

Published: May 29, 2025

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study.

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real-Life Study.

Journal: International journal of dermatology

Published: May 03, 2025

Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy.

Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy.

Journal: Clinical and experimental dermatology

Published: March 14, 2025

Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study.

Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study.

Journal: The Journal of dermatology

Published: January 22, 2025

Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies.

Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies.

Journal: Dermatology reports

Published: November 21, 2024

Eczematous liraglutide eruption managed by dupilumab: A case report.

Eczematous liraglutide eruption managed by dupilumab: A case report.

Journal: JAAD case reports

Published: October 21, 2024

Comment on 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council': a case of rhabdomyolysis induced by upadacitinib.

Comment on 'A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council': a case of rhabdomyolysis induced by upadacitinib.

Journal: The British journal of dermatology

Published: September 15, 2024

Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.

Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience.

Journal: Journal of clinical medicine

Published: August 07, 2024

Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.

Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.

Journal: Expert opinion on biological therapy

Published: March 27, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026